News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Neuroscience, Inc. (TEVA): New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE(R) is More Cost Effective Than Tysabri(R) for Treatment of Relapsing-Remitting Multiple Sclerosis



10/25/2007 9:36:41 AM

KANSAS CITY, Mo.--(BUSINESS WIRE)--In a Markov cost-effectiveness model, a comparison of the long-term economic outcomes associated with COPAXONE® (glatiramer acetate injection), and Tysabri® (natalizumab) combined with symptom management versus symptom management alone demonstrated that COPAXONE® was less costly and more effective over a patient’s lifetime than Tysabri® for relapsing-remitting multiple sclerosis (RRMS). Results, announced today at the 10th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) congress in Dublin, Ireland, incorporate Tysabri® in an analysis of an updated Markov model previously published in the Journal of Managed Care Pharmacy in April 2007.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES